Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds

被引:112
作者
Enokizono, Junichi [1 ]
Kusuhara, Hiroyuki [1 ]
Ose, Atsushi [1 ]
Schinkel, Alfred H. [2 ]
Sugiyama, Yuichi [1 ]
机构
[1] Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan
[2] Netherlands Canc Inst, Div Expt Therapy, NL-1066 CX Amsterdam, Netherlands
关键词
D O I
10.1124/dmd.107.019257
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The role of breast cancer resistance protein (BCRP/ABCG2) in limiting the brain and testis penetration of xenobiotic compounds in the blood-brain and -testis barriers was investigated using Bcrp(-/-) mice. Tissue/plasma concentration ratios in the brain (K-p,K-brain) and testis ( K-p,K-testis) obtained under steady-state conditions were significantly increased in Bcrp(-/-) mice for PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine), N-hydroxyl PhIP, MeIQx (2-amino3,8-dimethylimidazo[4,5-f]quinoxaline), dantrolene, and prazosin. In addition, the K-p,K-brain of triamterene and the K-p,K-testis of 4 '-hydroxyl PhIP were also significantly increased in Bcrp(-/-) mice. The effect of functional impairment of Bcrp on the brain uptake of PhIP, dantrolene, and daidzein in Bcrp(-/-) mice determined using in situ brain perfusion was weaker than that observed on the Kp values. In vitro transcellular transport experiments using cell lines expressing mouse Bcrp or P-glycoprotein (Mdr1a/Abcb1a) showed that, among the tested Bcrp substrates, PhIP, MeIQx, prazosin, and triamterene are common substrates of Bcrp and P-glycoprotein. The Kp values of common substrates exhibited a smaller increase both in the brain and testis of Bcrp(-/-) mice than expected from the in vitro Bcrp activities. The Bcrp-specific substrates were weak acids, whereas basic or neutral BCRP substrates were also P-glycoprotein substrates. These results suggest that BCRP limits the tissue penetration of xenobiotic compounds in the blood-brain and-testis barriers, but its in vivo importance is also modulated by P-glycoprotein activity.
引用
收藏
页码:995 / 1002
页数:8
相关论文
共 42 条
[1]   Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen [J].
Adachi, Y ;
Suzuki, H ;
Schinkel, AH ;
Sugiyama, Y .
MOLECULAR PHARMACOLOGY, 2005, 67 (03) :923-928
[2]   Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein [J].
Adachi, Y ;
Suzuki, H ;
Sugiyama, Y .
PHARMACEUTICAL RESEARCH, 2001, 18 (12) :1660-1668
[3]   Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones [J].
Ando, Tomohiro ;
Kusuhara, Hiroyuki ;
Merino, Gracia ;
Alvarez, Ana I. ;
Schinkel, Alfred H. ;
Sugiyama, Yuichi .
DRUG METABOLISM AND DISPOSITION, 2007, 35 (10) :1873-1879
[4]   Xenobiotic and endobiotic transporter mRNA expression in the blood-testis barrier [J].
Augustine, LM ;
Markelewicz, RJ ;
Boekelheide, K ;
Cherrington, NJ .
DRUG METABOLISM AND DISPOSITION, 2005, 33 (01) :182-189
[5]   Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione [J].
Bai, J ;
Lai, LQ ;
Yeo, HC ;
Goh, BC ;
Tan, TMC .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2004, 36 (02) :247-257
[6]   The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours [J].
Bart, J ;
Hollema, H ;
Groen, HJM ;
de Vries, EGE ;
Hendrikse, NH ;
Sleijfer, DT ;
Wegman, TD ;
Vaalburg, W ;
van der Graaf, WTA .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (14) :2064-2070
[7]   An oncological view on the blood-testis barrier [J].
Bart, J ;
Groen, HJM ;
van der Graaf, WTA ;
Hollema, H ;
Hendrikse, NH ;
Vaalburg, W ;
Sleijfer, DT ;
de Vries, EGE .
LANCET ONCOLOGY, 2002, 3 (06) :357-363
[8]   Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec®) across the mouse blood-brain barrier [J].
Bihorel, Sebastien ;
Camenisch, Gian ;
Lemaire, Michel ;
Scherrmann, Jean-Michel .
JOURNAL OF NEUROCHEMISTRY, 2007, 102 (06) :1749-1757
[9]   The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients [J].
Breedveld, P ;
Pluim, D ;
Cipriani, G ;
Wielinga, P ;
van Tellingen, O ;
Schinkel, AH ;
Schellens, JHM .
CANCER RESEARCH, 2005, 65 (07) :2577-2582
[10]   Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump [J].
Burger, H ;
van Tol, H ;
Boersma, AWM ;
Brok, M ;
Wiemer, EAC ;
Stoler, G ;
Nooter, K .
BLOOD, 2004, 104 (09) :2940-2942